THE US Food and Drug Administration has released further details of its 2018 Compounding Priorities Plan, with a key focus being to ensure the quality of compounded medications.
New draft guidance contains a series of recommendations for protecting patients from the risk of contaminated or substandard products produced by compounding pharmacies.
A particular concern is ongoing "unsafe activity in the compounding sector," including at facilities which are not registered with the FDA as outsourcing facilities but which continue to distribute "office stock" for health providers to give to patients.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Dec 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Dec 18